Clinical Trials Logo
  1. Home
  2. Thymoma and Thymic Carcinoma
  3. NCT02636556

Chemoradiotherapy for Limited Advanced Unresectable Thymic Epithelial Tumors

Thymoma and Thymic Carcinoma Clinical Trial

Official title:
Phase Ⅱ Study of Concurrent Chemoradiotherapy for Limited Advanced Unresectable Thymic Epithelial Tumors

Clinical Trial Summary

This study is designed to evaluate the feasibility and safety of concurrent chemoradiotherapy for limited advanced unresectable thymoma or thymic carcinoma.

Clinical Trial Description

Complete resection is difficult to achieve without damaging the main organs in advanced thymoma or thymic carcinoma. The previous trials have showed that radiotherapy was significantly associated with prolonged OS and chemotherapy is playing an increasing role in treatment of patients with advanced thymoma or thymic carcinoma. However, whether concurrent chemoradiotherapy is safety in advanced thymoma or thymic carcinoma is still unknown. The purpose of this study is to evaluate the feasibility and safety of concurrent chemoradiotherapy for limited advanced unresectable thymoma or thymic carcinoma. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02636556
Study type Interventional
Source Fudan University
Contact
Status Completed
Phase N/A
Start date June 2011
Completion date February 2020
View Details
See also
  Status Clinical Trial Phase
Completed NCT00003283 - Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma Phase 2
Completed NCT00372840 - Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer N/A
Completed NCT00024076 - Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer Phase 2
Completed NCT02049047 - Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy Phase 2
Recruiting NCT02633514 - Adjuvant Treatment for Incomplete Resection Thymoma or Thymic Carcinoma Phase 3
Recruiting NCT04554524 - Chemotherapy Combined With Pembrolizumab in Treating Patients With Thymoma and Thymic Carcinoma Phase 4
Active, not recruiting NCT03663764 - Hypofractionated Chemoradiotherapy and Thymosin α1 in Unresectable or Recurrent Thymic Epithelial Tumor Phase 2
Recruiting NCT06301945 - Artificial Intelligence Prediction Tool in Thymic Epithelial Tumors